PL3288379T3 - Kompozycje peptydowe i sposoby stosowania - Google Patents

Kompozycje peptydowe i sposoby stosowania

Info

Publication number
PL3288379T3
PL3288379T3 PL16789830T PL16789830T PL3288379T3 PL 3288379 T3 PL3288379 T3 PL 3288379T3 PL 16789830 T PL16789830 T PL 16789830T PL 16789830 T PL16789830 T PL 16789830T PL 3288379 T3 PL3288379 T3 PL 3288379T3
Authority
PL
Poland
Prior art keywords
methods
peptide compositions
peptide
compositions
Prior art date
Application number
PL16789830T
Other languages
English (en)
Inventor
Cagri G. Besirli
Alexander J. Bridges
John K. Freshley
William A. Hunke
Linda L. Johnson
Francis X. Smith
Ethan SYLVAIN
David N. Zacks
Original Assignee
Onl Therapeutics, Inc.
The Regents Of The University Of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onl Therapeutics, Inc., The Regents Of The University Of Michigan filed Critical Onl Therapeutics, Inc.
Publication of PL3288379T3 publication Critical patent/PL3288379T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pest Control & Pesticides (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PL16789830T 2015-05-01 2016-04-29 Kompozycje peptydowe i sposoby stosowania PL3288379T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562155711P 2015-05-01 2015-05-01
PCT/US2016/030098 WO2016178993A1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use
EP16789830.3A EP3288379B1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use

Publications (1)

Publication Number Publication Date
PL3288379T3 true PL3288379T3 (pl) 2022-03-07

Family

ID=57217771

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16789830T PL3288379T3 (pl) 2015-05-01 2016-04-29 Kompozycje peptydowe i sposoby stosowania

Country Status (22)

Country Link
US (4) US10508134B2 (pl)
EP (2) EP3997981A1 (pl)
JP (2) JP6884755B2 (pl)
KR (2) KR102652804B1 (pl)
CN (2) CN113651873A (pl)
AU (1) AU2016258837B2 (pl)
BR (1) BR112017023479A2 (pl)
CA (1) CA2984154A1 (pl)
CY (1) CY1124911T1 (pl)
DK (1) DK3288379T3 (pl)
EA (2) EA035293B1 (pl)
ES (1) ES2906173T3 (pl)
HK (1) HK1251979A1 (pl)
HR (1) HRP20220138T1 (pl)
HU (1) HUE057883T2 (pl)
LT (1) LT3288379T (pl)
MX (1) MX2017014075A (pl)
PL (1) PL3288379T3 (pl)
PT (1) PT3288379T (pl)
RS (1) RS62866B1 (pl)
SI (1) SI3288379T1 (pl)
WO (1) WO2016178993A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3288379T (lt) * 2015-05-01 2022-02-25 Onl Therapeutics, Inc. Peptidų kompozicijos ir naudojimo būdai
WO2019183246A1 (en) * 2018-03-20 2019-09-26 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
EP3810082A1 (en) * 2018-06-19 2021-04-28 Cella Therapeutics, LLC Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
JP2023507603A (ja) * 2019-12-18 2023-02-24 セラ セラピューティクス エルエルシー 神経栄養剤、アポトーシスシグナリング断片化阻害剤（ＦＡＳ）もしくはＦＡＳリガンド（ＦＡＳＬ）阻害剤、腫瘍壊死因子α（ＴＮＦ－α）もしくはＴＮＦ受容体阻害剤、ミトコンドリアペプチド、オリゴヌクレオチド、ケモカイン阻害剤、またはシステイン－アスパラギン酸プロテアーゼ阻害剤を含む薬剤送達系
WO2023129766A1 (en) * 2021-12-27 2023-07-06 Onl Therapeutics, Inc. Sfasl for inhibiting rpe cell death and associated disorders
WO2024031024A1 (en) * 2022-08-05 2024-02-08 Onl Therapeutics, Inc. Peptide compositions and methods of use
WO2024031022A2 (en) * 2022-08-05 2024-02-08 Onl Therapeutics, Inc. Peptide compositions and methods of use

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5532123A (en) * 1990-07-11 1996-07-02 New York University Receptor-type phosphotyrosine phosphatase-γ
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
JP3187201B2 (ja) * 1992-05-14 2001-07-11 三共株式会社 Ｃ末端にプロリンアミドを有するペプチドの製法
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
JP3460863B2 (ja) 1993-09-17 2003-10-27 三菱電機株式会社 半導体装置の製造方法
US5714353A (en) 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5711964A (en) 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US6001962A (en) * 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
US7091047B2 (en) * 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US6363020B1 (en) 1999-12-06 2002-03-26 Virage Logic Corp. Architecture with multi-instance redundancy implementation
US6480428B2 (en) 2000-12-19 2002-11-12 Winbond Electronics Corporation Redundant circuit for memory device
AU2005230854A1 (en) * 2004-03-31 2005-10-20 Xencor, Inc BMP-7 variants with improved properties
CA2563691A1 (en) 2004-04-23 2005-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Cell death modulation via antagonists of fasl and fas activation
PL1885336T3 (pl) * 2005-05-10 2009-08-31 Alcon Inc Kompozycja w postaci zawiesiny zawierająca substancję aktywną, poloksamerowy lub meroksapolowy surfaktant i glikol oraz zastosowanie kompozycji do wytwarzania leku do leczenia chorób oczu
KR20080065704A (ko) * 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 의학적 이상의 치료 방법들, 조성물들, 및 키트들
EP1963364A2 (en) * 2005-12-01 2008-09-03 University of Pittsburgh - Of the Commonwealth System of Higher Education Compounds and methods for inhibiting apoptosis
AU2008345689B2 (en) * 2007-12-21 2013-04-18 Stryker Corporation BMP mutants with decreased susceptibility to Noggin
JP5643237B2 (ja) * 2009-03-03 2014-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 光受容細胞のアポトーシスを抑制する方法
EP2415478A4 (en) * 2009-03-30 2013-01-16 Santen Pharmaceutical Co Ltd PROPHYLAXIS OR THERAPY AGENTS FOR KIDNEY DISEASES AND METHODS OF PREVENTING OR TREATING NURSE DISEASES, EACH OF THEM WITH A JNK (C-JUN-N-TERMINAL KINASE) -IMBING PEPTIDE, AND USE OF THE PEPTIDE
EP2462128B1 (en) * 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
CN103492574B (zh) 2011-02-22 2015-12-09 加州理工学院 使用腺相关病毒（aav）载体递送蛋白
KR20140038501A (ko) * 2011-06-06 2014-03-28 키네타 원, 엘엘씨 Shk-기초된 제약학적 조성물 및 이들을 제조하고 이용하는 방법
WO2013106909A1 (en) 2012-01-18 2013-07-25 Governing Council Of The University Of Toronto Novel peptides and methods and uses thereof for preventing retinal disorders
US9580490B2 (en) * 2012-06-21 2017-02-28 Hanall Biopharma Co., Ltd. Uses of modified human tumor necrosis factor receptor-1 polypeptide
US20150265679A1 (en) * 2012-11-02 2015-09-24 The United States Of America, As Represented By Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor
CN107533048A (zh) 2015-02-05 2018-01-02 美国免疫阵列公司 用于诊断脑损伤或神经退行性变的方法和组合物
LT3288379T (lt) 2015-05-01 2022-02-25 Onl Therapeutics, Inc. Peptidų kompozicijos ir naudojimo būdai
US20190201500A1 (en) 2015-05-01 2019-07-04 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
KR20190096329A (ko) 2016-07-05 2019-08-19 유니버시티 오브 매사추세츠 녹내장에서 신경보호 요법으로서 sfasl의 aav2-매개된 유전자 전달
WO2019183246A1 (en) 2018-03-20 2019-09-26 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
EP3810082A1 (en) 2018-06-19 2021-04-28 Cella Therapeutics, LLC Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension

Also Published As

Publication number Publication date
US20230287052A1 (en) 2023-09-14
EP3997981A1 (en) 2022-05-18
BR112017023479A2 (pt) 2018-07-24
CY1124911T1 (el) 2023-01-05
KR20240046280A (ko) 2024-04-08
US11597749B2 (en) 2023-03-07
US20200123201A1 (en) 2020-04-23
DK3288379T3 (da) 2022-02-07
CN113651873A (zh) 2021-11-16
EA202090184A3 (ru) 2020-07-31
LT3288379T (lt) 2022-02-25
EP3288379B1 (en) 2021-11-03
CN107708416B (zh) 2021-06-29
JP2018514590A (ja) 2018-06-07
KR20170140383A (ko) 2017-12-20
EP3288379A1 (en) 2018-03-07
AU2016258837B2 (en) 2020-12-03
EA035293B1 (ru) 2020-05-26
CA2984154A1 (en) 2016-11-10
US10508134B2 (en) 2019-12-17
JP2021120400A (ja) 2021-08-19
EA201792399A1 (ru) 2018-05-31
ES2906173T3 (es) 2022-04-13
SI3288379T1 (sl) 2022-06-30
AU2016258837A1 (en) 2017-11-09
RS62866B1 (sr) 2022-02-28
KR102652804B1 (ko) 2024-04-01
US20210094985A1 (en) 2021-04-01
EP3288379A4 (en) 2018-10-24
EA202090184A2 (ru) 2020-05-31
US20180291062A1 (en) 2018-10-11
HUE057883T2 (hu) 2022-06-28
JP6884755B2 (ja) 2021-06-09
HRP20220138T1 (hr) 2022-05-27
US10829518B2 (en) 2020-11-10
CN107708416A (zh) 2018-02-16
MX2017014075A (es) 2018-07-06
PT3288379T (pt) 2022-02-08
HK1251979A1 (zh) 2019-05-10
WO2016178993A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
GB2582482B (en) CASZ compositions and methods of use
HK1252870A1 (zh) Sirp多肽組合物和使用方法
HK1247238B (zh) 改造的crispr-cas9組合物和使用方法
IL251834A0 (en) Pharmaceutical compositions containing peptide variants and methods of using them
GB2582100B (en) CAS12C Compositions and methods of use
HK1248531A1 (zh) 免疫調節組合物及其使用方法
ZA201701909B (en) Trichoderma compositions and methods of use
HK1251979A1 (zh) 肽組合物和使用方法
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
IL284236A (en) Modifications and uses of conotoxin peptides
ZA201906169B (en) Synthekine compositions and methods of use
HK1254960A1 (zh) 冷沉澱物組合物及其製備方法
HK1252057A1 (zh) 新穎的使用方法和組合物
HK1250345A1 (zh) 包含15-氧代-epa或15-氧代-dgla的組合物及其製備和使用方法
HK1247136A1 (zh) 包含15-hepe的組合物和其使用方法
IL256843B (en) Cleaning products and methods of using them
HK1243404A1 (zh) 色酰胺組合物和使用方法
HK1248527A1 (zh) 牙科組合物和使用方法
IL261794A (en) Preparations and methods for using them
IL247645A0 (en) Preparations of seleno-organic compounds and methods of using them